Long acting muscarinic antagonist trang 1 tải miễn phí từ TAILIEUCHUNG

"Long acting muscarinic antagonist" trang 1 - tải miễn phí từ Tailieuchung

A blinded evaluation of the efficacy and safety of glycopyrronium, a once-daily long-acting muscarinic antagonist, versus tiotropium, in patients with COPD: The GLOW5 study

A blinded evaluation of the efficacy and safety of glycopyrronium, a once-daily long-acting muscarinic antagonist, versus tiotropium, in patients with COPD: The GLOW5 study

11 23 1

Efficacy of revefenacin, a long-acting muscarinic antagonist for nebulized therapy, in patients with markers of more severe COPD: A post hoc subgroup analysis

Efficacy of revefenacin, a long-acting muscarinic antagonist for nebulized therapy, in patients with markers of more severe COPD: A post hoc subgroup analysis

10 20 1

A randomized controlled trial of long-acting muscarinic antagonist and long-acting β2 agonist fixed-dose combinations in patients with chronic obstructive pulmonary disease

A randomized controlled trial of long-acting muscarinic antagonist and long-acting β2 agonist fixed-dose combinations in patients with chronic obstructive pulmonary disease

8 17 1

Comparison of resource use by COPD patients on inhaled therapies with long-acting bronchodilators: A database study

Comparison of resource use by COPD patients on inhaled therapies with long-acting bronchodilators: A database study

9 24 1

Dose response of umeclidinium administered once or twice daily in patients with COPD: A randomised cross-over study

Dose response of umeclidinium administered once or twice daily in patients with COPD: A randomised cross-over study

14 10 1

Randomized study of the safety, pharmacokinetics, and bronchodilatory efficacy of a proprietary glycopyrronium metered-dose inhaler in study patients with chronic obstructive pulmonary disease

Randomized study of the safety, pharmacokinetics, and bronchodilatory efficacy of a proprietary glycopyrronium metered-dose inhaler in study patients with chronic obstructive pulmonary disease

10 13 1

Transient paradoxical bronchospasm associated with inhalation of the LAMA AZD9164: Analysis of two Phase I, randomised, double-blind, placebo-controlled studies

Transient paradoxical bronchospasm associated with inhalation of the LAMA AZD9164: Analysis of two Phase I, randomised, double-blind, placebo-controlled studies

13 21 1

Treatment with LABA versus LAMA for stable COPD: A systematic review and meta-analysis

Treatment with LABA versus LAMA for stable COPD: A systematic review and meta-analysis

11 32 1

Prognostic and functional impact of perioperative LAMA/LABA inhaled therapy in patients with lung cancer and chronic obstructive pulmonary disease

Prognostic and functional impact of perioperative LAMA/LABA inhaled therapy in patients with lung cancer and chronic obstructive pulmonary disease

11 37 3

Đã phát hiện trình chặn quảng cáo AdBlock

Trang web này phụ thuộc vào doanh thu từ số lần hiển thị quảng cáo để tồn tại. Vui lòng tắt trình chặn quảng cáo của bạn hoặc tạm dừng tính năng chặn quảng cáo cho trang web này.